News

Algorithm acquires pump for PulmoProst, potential PAH therapy

Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…

Liquidia licenses rights in North America to inhaled L606 for PH

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…

Janssen seeks approval in Europe for PAH combination therapy tablet

Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…

Pregnancy more likely to be favorable if mother’s PH is mild

Pregnant women with mild pulmonary hypertension (PH) show a significantly lower risk of maternal and fetal complications than those with moderate-to-severe PH, according to a study from China. “For patients with mild pulmonary hypertension and good cardiac function, continued pregnancy or even delivery should be considered under multidisciplinary monitoring,”…

Study examines long-term prognosis of CTEPH after blood clot

Developing chronic thromboembolic pulmonary hypertension (CTEPH) within two years after a venous thromboembolism (VTE), which occurs when a blood clot forms in a vein, nearly doubles the risk of long-term death, according to a large study from Denmark. Researchers also observed that all types of pulmonary hypertension (PH)…

More than 50% of preterm babies with PH respond to Revatio: Study

Treatment with intravenous Revatio (sildenafil) can improve oxygen delivery and heart health in some premature babies with pulmonary hypertension, although more than four in 10 patients don’t respond to it. “Our study adds new insights on preterm and [very low birth weight]-infants with sildenafil treatment for primary early PH…

Muscle strengthening may complement PAH therapies

Persistent exercise intolerance in pulmonary arterial hypertension (PAH) patients with treatment-related improvements in blood pressure was associated with impaired muscle function and strength, a study revealed. Because many of the study’s participants have lived with PAH for many years, muscle function may have been compromised, the researchers noted. Interventions…

Better ways sought to gauge patients’ experiences in PAH trials

The outcomes used in clinical trials of pulmonary arterial hypertension (PAH) don’t fully reflect the priorities of patients and clinicians, a new study asserts. The study, “‘It’s that invisible illness’: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment,” was published in the journal…


A Conversation With Rare Disease Advocates